Comparative Pharmacology
Head-to-head clinical analysis: CEFOXITIN versus CEFTRIAXONE SODIUM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CEFOXITIN versus CEFTRIAXONE SODIUM.
CEFOXITIN vs CEFTRIAXONE SODIUM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cefoxitin is a cephamycin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), particularly PBP-1 and PBP-3, thereby inhibiting the final transpeptidation step of peptidoglycan synthesis. This leads to cell lysis and death. It is resistant to beta-lactamases produced by many Gram-negative and Gram-positive bacteria.
Ceftriaxone inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting transpeptidase activity, and disrupting peptidoglycan cross-linking.
1-2 g IV every 6-8 hours; maximum 12 g/day.
1-2 g IV/IM every 12-24 hours; maximum 4 g/day.
None Documented
None Documented
Clinical Note
moderateCefoxitin + Probenecid
"The serum concentration of Probenecid can be increased when it is combined with Cefoxitin."
Clinical Note
moderateCefoxitin + Picosulfuric acid
"The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Cefoxitin."
Clinical Note
moderateWarfarin + Cefoxitin
"Warfarin may increase the anticoagulant activities of Cefoxitin."
Clinical Note
moderatePhenprocoumon + Cefoxitin
Terminal elimination half-life is approximately 0.7–1.1 hours (mean 0.8 h) in adults with normal renal function, extending to 5–10 hours in severe renal impairment (CrCl <10 mL/min).
Terminal elimination half-life is 5.8-8.7 hours in adults with normal renal and hepatic function. In neonates, half-life is prolonged (up to 16 hours). In patients with renal impairment, half-life increases to 12-18 hours; in hepatic impairment, it may be 15-20 hours. Dose adjustment is not typically required unless both renal and hepatic impairment are present.
Renal excretion of unchanged drug accounts for approximately 85% of elimination; biliary excretion is minimal (<1%); fecal elimination is negligible.
Ceftriaxone is eliminated 33-67% unchanged in urine via glomerular filtration and tubular secretion, and the remainder is excreted in feces (primarily as microbiologically inactive metabolites) via biliary secretion. Biliary excretion accounts for approximately 35-45% of total clearance.
Category A/B
Category C
Cephalosporin Antibiotic
Cephalosporin Antibiotic
"Phenprocoumon may increase the anticoagulant activities of Cefoxitin."